University of California

Otonomy, Inc.

Amprion, Inc.

Afraxis Holdings, Inc.

University of Texas System

Dompe' Farmaceutici S.p.a.

House Ear Institute

Afraxis, Inc.

Neptune Biosciences LLC

Shahnawaz, Mohammad

Jara, Claudio Soto

Vollrath, Benedikt K.

Lebovitz, Russell M.

Benedikt K Vollrath

Luis A Dellamary

Fabrice Piu

Qiang Ye

Jay Lichter

Carl Lebel

Andrew M Trammel

Jeffrey P Harris

Michael Christopher Scaife

Sergio G Duron

Sergio G Durón

Russell M Lebovitz

Warren Stanfield Wade

David Alan Campbell

Mohammad Shahnawaz

Luis Concha

Carly Farris

Bret Holguin

Claudio Soto Jara

Frank Espin

Sridhar Govindarajan

Claudio Soto-Jara

Rick Friedman

Nigel Killeen

Oren Beske

Nicolas Mendez Dinamarca

Orthogonal IL-21 receptors and orthogonal IL-21 cytokines are described. The IL-21 receptor-cytokine pairs may include an orthogonal interleukin-21 receptor α chain ('ortho-IL-21Rα') that has impaired binding to native interleukin-21 cytokine (“IL-21”) and an orthogonal IL-21 cytokine (“ortho-IL-21”) that has impaired binding to native IL-21Rα, wherein the ortho-IL-21Rα binds to the ortho-IL-21. The IL-21 receptor-cytokine pair may activate IL-21 signaling. Cells engineered to express the orthogonal IL-21 receptors are also described, as well as methods for using such cells for treatment of various diseases and disorders.

Engineered human IL-21 cytokines and methods for using the same

Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

Auris formulations for treating otic diseases and conditions

A method is provided for determining the presence of soluble, misfolded α-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric α-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded α-synuclein aggregate is present in the biological sample.

Alpha-synuclein detection using beads

Methods and kits are provided for amplifying and detecting misfolded tau protein from samples, for example, from patients having tauopathies such as Alzheimer's Disease, Progressive Supranuclear Palsy, and the like.

Detection of misfolded tau protein

A method is provided for determining the presence of soluble, misfolded &#x3b1;-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric &#x3b1;-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded &#x3b1;-synuclein aggregate is present in the biological sample.

Methods and kits are provided for amplifying and detecting &#x3b1;S proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded &#x3b1;S protein may include: contacting the sample with a monomeric, folded &#x3b1;S protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded &#x3b1;S protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded &#x3b1;S protein in the presence of the soluble, misfolded &#x3b1;S protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded &#x3b1;S aggregate present; and determining the presence of the soluble, misfolded &#x3b1;S protein in the sample by detecting at least a portion of the soluble, misfolded &#x3b1;S protein.

Detection of misfolded alpha synuclein protein

Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Controlled-release CNS modulating compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with aural pressure modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders

Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders

Methods and kits are provided for amplifying and detecting A&#x3b2; proteins from samples, for example, from patients having Alzheimer's Disease. For example, a method for determining a presence of a soluble, misfolded A&#x3b2; protein may include contacting the sample with a monomeric, folded A&#x3b2; protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded A&#x3b2; protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded A&#x3b2; protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded A&#x3b2; aggregate present; and determining the presence of the soluble, misfolded A&#x3b2; protein in the sample by detecting at least a portion of the amplified portion of misfolded A&#x3b2; protein.

Detection of misfolded amyloid beta protein

Disclosed herein are auris acceptable gel compositions containing a multiparticulate glutamate receptor antagonist, and methods for the treatment of otic diseases or conditions through intratympanic administration of the composition to an individual afflicted with an otic disease or condition.

Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Described herein are compositions and methods of treating and/or preventing inner ear conditions by administering to a patient in need thereof a modulator of a metabotropic glutamate receptor.

Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor

Disclosed herein are thermoreverisble gel compositions containing a multiparticulate glutamate receptor antagonist, and methods for the treatment of otic diseases or conditions through intratympanic administration of the composition to an individual afflicted with an otic disease or condition.

Growing community of inventors

San Diego, CA, United States of America

Benedikt K Vollrath